Labroots

Treatment Schedule of Chemoradiotherapy for Nasopharyngeal Carcinoma

Nasopharyngeal carcinoma (NPC), a malignancy that develops in the upper section of the throat behind the nose, occurs in fewer than one person out of 100,000 worldwide each year. Locally advanced ...
Monthly Prescribing Reference

Nasopharyngeal Carcinoma Treatment Loqtorzi Now Available

Credit: Coherus BioSciences. Coherus has launched the Loqtorzi Solutions program, which provides support services to prescribers and patients. Loqtorzi (toripalimab-tpzi) is now available for the ...
Healio

Treatment deintensification a ‘promising alternative’ for nasopharyngeal carcinoma

Please provide your email address to receive an email when new articles are posted on . Researchers found nearly identical 3-year PFS data among the two cohorts. Grade 3 and 4 short-term toxic effects ...
Healio

Benefit of radiotherapy for nasopharyngeal carcinoma may vary by time of day

Please provide your email address to receive an email when new articles are posted on . Patients with nasopharyngeal cancer who received morning radiotherapy survived longer than those treated later ...
Morningstar

European Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved TEVIMBRA® (tislelizumab), in combination with ...
ascopubs.org

Updates on Treatments and Management of Nasopharyngeal Carcinoma

Nasopharyngeal carcinoma (NPC) is a unique head and neck cancer, where the endemic subtype is strongly associated with Epstein-Barr virus (EBV) infection, whereas emerging data suggest that a subset ...
Medscape

Statins Plus Nasopharyngeal Cancer Treatment Associated With Reduced Mortality

Statin use during concurrent chemoradiotherapy (CCRT) for advanced nasopharyngeal cancer (NPC) is associated with a 52% reduction in all-cause mortality. Higher cumulative defined daily doses of ...
Nasdaq

Akeso's Penpulimab Gets NMPA Approval For First-Line Treatment Of Nasopharyngeal Cancer

(RTTNews) - Biopharmaceutical company Akeso Inc. (AKESF) said in a statement that its Penpulimab has been approved for the first-line treatment of recurrent or metastatic nasopharyngeal cancer or NPC, ...
ascopubs.org

Treatment of Childhood Nasopharyngeal Carcinoma With Induction Chemotherapy and Concurrent Chemoradiotherapy: Results of the Children’s Oncology Group ARAR0331 Study

Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium Patients with American Joint Committee ...
KXAN

Global Launch Event for iza-bren Phase III Nasopharyngeal Carcinoma Research Results Successfully Held, Streamed on ESMO Official Website

Nasopharyngeal Carcinoma Leads Solid Tumor Treatment into the Bispecific ADC Era Professor Huaqiang Zhou provided a systematic and in-depth interpretation of the 303 Study, pointing out that this ...
EurekAlert!

Landmark study uncovers role of tumor microenvironment in nasopharyngeal carcinoma progression which supports personalized treatment

Molecular profiling of over 1,000 nasopharyngeal cancer (NPC) patients’ tumours reveals distinct differences in tumour microenvironment of locoregionally advanced NPC, supporting the use of ...